Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 76 followers
Latest posts
Last updated 1 day ago
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
1 day ago
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening...
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
2 days ago
Novartis showcases significant immunology advancements in ACR congress with new data in...
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
6 days ago
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial...
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
6 days ago
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer...
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
8 days ago
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer arcticnovartis...
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
11 days ago
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence...
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
11 days ago
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with...
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
12 days ago
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline...
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
27 days ago
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi...
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
29 days ago
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US arcticnovartis...
Novartis announces commencement of tender offer to acquire Tourmaline Bio
29 days ago
Novartis announces commencement of tender offer to acquire Tourmaline Bio arcticnovartis Mon...
Bringing breakthroughs to more patients
29 days ago
Bringing breakthroughs to more patients angilma1 Sun, 09/28/2025 - 21:39 Read more...